Sai Parenteral's Limited has announced a board of directors meeting scheduled for April 20, 2026, to deliberate on a significant investment proposal involving its Australian step-down subsidiary. The meeting represents a strategic corporate development as the company explores expansion opportunities in international markets.

Meeting Details and Agenda

The board meeting is scheduled for April 20, 2026, at 12:00 p.m. at the company's registered office. The primary agenda focuses on a proposal to invest in or provide lending to Noumed Pharmaceuticals Pty Limited, Australia, which operates as a step-down subsidiary of Sai Parenteral's Limited.

Investment Structure and Compliance

The proposed investment will be channeled through Sai Parenterals PTE Limited, which serves as the company's wholly owned subsidiary. This structure demonstrates the company's strategic approach to international investments through established subsidiary networks. The investment proposal is subject to necessary approvals and must comply with applicable laws governing cross-border investments.

Regulatory Compliance

The meeting notice was issued on April 14, 2026, in accordance with Regulation 29(1)(d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This regulation mandates prior intimation to stock exchanges regarding board meetings that may consider material business decisions.

The company has formally notified both BSE Limited (Scrip Code: 544742) and National Stock Exchange of India Limited (Symbol: SAIPARENT) about the scheduled meeting. The notice was signed by Anil Kumar Karusala, Chairman and Managing Director (DIN: 01866646), ensuring proper corporate governance protocols are followed.

Additional Considerations

The board meeting agenda also includes provisions for considering any other matters with the permission of the Chair, allowing flexibility for additional business discussions that may arise during the meeting. This standard practice ensures comprehensive coverage of corporate matters requiring board attention.

Sai Parenteral Limited has notified stock exchanges regarding the authorization of key managerial personnel for regulatory disclosure purposes. The company communicated this development to both BSE Limited and National Stock Exchange of India Limited on April 06, 2026, ensuring compliance with SEBI regulations.

Authorized Personnel Details

Under Regulation 30(5) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the company has designated three key managerial personnel as authorized persons for determining materiality of events and making disclosures to stock exchanges.

These authorized persons are severally empowered to determine the materiality of events or information and handle disclosure requirements to stock exchanges on behalf of the company.

Regulatory Compliance

The intimation was formally submitted to the listing departments of both major Indian stock exchanges. BSE Limited, where the company trades under scrip code 544742, and National Stock Exchange of India Limited, where it is listed under the symbol SAIPARENT, received the notification simultaneously.

The communication was digitally signed by Anil Kumar Karusala, Managing Director with DIN 01866646, on April 06, 2026. This authorization framework ensures that the company maintains proper governance structure for regulatory communications and compliance with SEBI's listing obligations.